Healthcare provider profile · identity verified

Maria Doubrovskaia, MD

Internal Medicine · FARMVILLE, VA · NPI 1760601306

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	184	35
Eliquis	Apixaban	144	22
Amlodipine Besylate	Amlodipine Besylate	115	25
Buspirone Hcl	Buspirone Hcl	91	15
Trazodone Hcl	Trazodone Hcl	89	15
Levothyroxine Sodium	Levothyroxine Sodium	81	18
Furosemide	Furosemide	67	17
Metoprolol Tartrate	Metoprolol Tartrate	66	16
Duloxetine Hcl	Duloxetine Hcl	64	suppressed
Mirtazapine	Mirtazapine	61	14
Baclofen	Baclofen	60	12
Diclofenac Sodium	Diclofenac Sodium	60	12
Entresto	Sacubitril/Valsartan	54	suppressed
Donepezil Hcl	Donepezil Hcl	51	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	51	11
Allopurinol	Allopurinol	50	11
Carvedilol	Carvedilol	50	12
Clopidogrel	Clopidogrel Bisulfate	49	12
Incruse Ellipta	Umeclidinium Bromide	49	suppressed
Famotidine	Famotidine	48	suppressed
Spironolactone	Spironolactone	46	suppressed
Lactulose	Lactulose	44	suppressed
Sertraline Hcl	Sertraline Hcl	43	11
Prednisone	Prednisone	41	suppressed
Rexulti	Brexpiprazole	40	suppressed
Metformin Hcl	Metformin Hcl	39	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	38	suppressed
Losartan Potassium	Losartan Potassium	35	suppressed
Potassium Chloride	Potassium Chloride	35	11
Montelukast Sodium	Montelukast Sodium	33	suppressed
Clonidine Hcl	Clonidine Hcl	32	suppressed
Metoprolol Succinate	Metoprolol Succinate	32	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	32	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Hydralazine Hcl	Hydralazine Hcl	30	suppressed
Methenamine Hippurate	Methenamine Hippurate	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Gabapentin	Gabapentin	28	16
Klor-Con 10	Potassium Chloride	28	suppressed
Trulicity	Dulaglutide	28	suppressed
Aripiprazole	Aripiprazole	27	suppressed
Bumetanide	Bumetanide	27	12
Risperidone	Risperidone	27	suppressed
Benztropine Mesylate	Benztropine Mesylate	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	26	suppressed
Jardiance	Empagliflozin	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Colestipol Hcl	Colestipol Hcl	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	21	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Omeprazole	Omeprazole	21	suppressed
Lisinopril	Lisinopril	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Olanzapine	Olanzapine	20	suppressed
Oxcarbazepine	Oxcarbazepine	19	suppressed
Latanoprost	Latanoprost	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	15	suppressed
Dilantin	Phenytoin Sodium Extended	14	suppressed
Finasteride	Finasteride	14	suppressed
Topiramate	Topiramate	14	suppressed
Bromocriptine Mesylate	Bromocriptine Mesylate	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Atenolol	Atenolol	12	suppressed
Budesonide	Budesonide	12	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	12	suppressed
Formoterol Fumarate	Formoterol Fumarate	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Oxaprozin	Oxaprozin	12	suppressed
Valsartan	Valsartan	12	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Nystatin	Nystatin	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error